Phase 2 Multicentric Study Evaluating the Efficacy of Omalizumab in Idiopathic Severe and Refractory Solar Urticaria
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2018
Price : $35 *
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 27 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 13 Oct 2014 New trial record